Skip to main content
PMC home page
Journal of Psychiatry & Neuroscience : JPN logoLink to Journal of Psychiatry & Neuroscience : JPN
. 2000 Nov;25(5):459–468.

Premenstrual syndrome and premenstrual dysphoric disorder: guidelines for management

M Steiner 1
PMCID: PMC1408015  PMID: 11109297

Abstract

The inclusion of research diagnostic criteria for premenstrual dysphoric disorder (PMDD) in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, recognizes the fact that some women have extremely distressing emotional and behavioural symptoms premenstrually. PMDD can be differentiated from premenstrual syndrome (PMS), which presents with milder physical symptoms, headache, and more minor mood changes. In addition, PMDD can be differentiated from premenstrual magnification of physical or psychological symptoms of a concurrent psychiatric or medical disorder. As many as 75% of women with regular menstrual cycles experience some symptoms of PMS, according to epidemiologic surveys. PMDD is much less common; it affects only 3% to 8% of women in this group. The etiology of PMDD is largely unknown, but the current consensus is that normal ovarian function (rather than hormone imbalance) is the cyclical trigger for PMDD-related biochemical events within the central nervous system and other target organs. The serotonergic system is in a close reciprocal relation with the gonadal hormones and has been identified as the most plausible target for interventions. Thus, beyond conservative treatment options such as lifestyle and stress management, other non-antidepressant treatments, or the more extreme intervneitons that eliminate ovulation altogether, selective serotonin reuptake inhibitors (SSRIs) are emerging as the most effective treatment option. Results from several randomized, placebo-controlled trials in women with PMDD have clearly demonstrated that SSRIs have excellent efficacy and minimal side effects. More recently, several preliminary studies indicate that intermittent (premenstrual only) treatment with selective SSRIs is equally effective in these women and, thus, may offer an attractive treatment option for a disorder that is itself intermittent.

Full text

PDF
459

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersch B. Bromocriptine and premenstrual symptoms: a survey of double blind trials. Obstet Gynecol Surv. 1983 Nov;38(11):643–646. doi: 10.1097/00006254-198311000-00001. [DOI] [PubMed] [Google Scholar]
  2. Bancroft J., Cook A., Davidson D., Bennie J., Goodwin G. Blunting of neuroendocrine responses to infusion of L-tryptophan in women with perimenstrual mood change. Psychol Med. 1991 May;21(2):305–312. doi: 10.1017/s0033291700020407. [DOI] [PubMed] [Google Scholar]
  3. Bancroft J., Cook A. The neuroendocrine response to d-fenfluramine in women with premenstrual depression. J Affect Disord. 1995 Dec 24;36(1-2):57–64. doi: 10.1016/0165-0327(95)00060-7. [DOI] [PubMed] [Google Scholar]
  4. Berger C. P., Presser B. Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder: a double-blind, placebo-controlled crossover study. Obstet Gynecol. 1994 Sep;84(3):379–385. [PubMed] [Google Scholar]
  5. Blake F., Salkovskis P., Gath D., Day A., Garrod A. Cognitive therapy for premenstrual syndrome: a controlled trial. J Psychosom Res. 1998 Oct;45(4):307–318. doi: 10.1016/s0022-3999(98)00042-7. [DOI] [PubMed] [Google Scholar]
  6. Brown C. S., Ling F. W., Andersen R. N., Farmer R. G., Arheart K. L. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol. 1994 Nov;84(5):779–786. [PubMed] [Google Scholar]
  7. Budeiri D. J., Li Wan Po A., Dornan J. C. Clinical trials of treatments of premenstrual syndrome: entry criteria and scales for measuring treatment outcomes. Br J Obstet Gynaecol. 1994 Aug;101(8):689–695. doi: 10.1111/j.1471-0528.1994.tb13186.x. [DOI] [PubMed] [Google Scholar]
  8. Casper R. F., Hearn M. T. The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. Am J Obstet Gynecol. 1990 Jan;162(1):105–109. doi: 10.1016/0002-9378(90)90831-q. [DOI] [PubMed] [Google Scholar]
  9. Casson P., Hahn P. M., Van Vugt D. A., Reid R. L. Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am J Obstet Gynecol. 1990 Jan;162(1):99–105. doi: 10.1016/0002-9378(90)90830-z. [DOI] [PubMed] [Google Scholar]
  10. Chambers C. D., Johnson K. A., Dick L. M., Felix R. J., Jones K. L. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996 Oct 3;335(14):1010–1015. doi: 10.1056/NEJM199610033351402. [DOI] [PubMed] [Google Scholar]
  11. Cohen I. R., Wise P. M. Effects of estradiol on the diurnal rhythm of serotonin activity in microdissected brain areas of ovariectomized rats. Endocrinology. 1988 Jun;122(6):2619–2625. doi: 10.1210/endo-122-6-2619. [DOI] [PubMed] [Google Scholar]
  12. Deeny M., Hawthorn R., McKay Hart D. Low dose danazol in the treatment of the premenstrual syndrome. Postgrad Med J. 1991 May;67(787):450–454. doi: 10.1136/pgmj.67.787.450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Endicott J., Amsterdam J., Eriksson E., Frank E., Freeman E., Hirschfeld R., Ling F., Parry B., Pearlstein T., Rosenbaum J. Is premenstrual dysphoric disorder a distinct clinical entity? J Womens Health Gend Based Med. 1999 Jun;8(5):663–679. doi: 10.1089/jwh.1.1999.8.663. [DOI] [PubMed] [Google Scholar]
  14. Endicott J. The menstrual cycle and mood disorders. J Affect Disord. 1993 Oct-Nov;29(2-3):193–200. doi: 10.1016/0165-0327(93)90033-g. [DOI] [PubMed] [Google Scholar]
  15. Eriksson E., Hedberg M. A., Andersch B., Sundblad C. The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology. 1995 Apr;12(2):167–176. doi: 10.1016/0893-133X(94)00076-C. [DOI] [PubMed] [Google Scholar]
  16. Eriksson E. Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria. Int Clin Psychopharmacol. 1999 May;14 (Suppl 2):S27–S33. [PubMed] [Google Scholar]
  17. Facchinetti F., Borella P., Sances G., Fioroni L., Nappi R. E., Genazzani A. R. Oral magnesium successfully relieves premenstrual mood changes. Obstet Gynecol. 1991 Aug;78(2):177–181. [PubMed] [Google Scholar]
  18. Facchinetti F., Fioroni L., Sances G., Romano G., Nappi G., Genazzani A. R. Naproxen sodium in the treatment of premenstrual symptoms. A placebo-controlled study. Gynecol Obstet Invest. 1989;28(4):205–208. doi: 10.1159/000293579. [DOI] [PubMed] [Google Scholar]
  19. Facchinetti F., Nappi R. E., Sances M. G., Neri I., Grandinetti G., Genazzani A. Effects of a yeast-based dietary supplementation on premenstrual syndrome. A double-blind placebo-controlled study. Gynecol Obstet Invest. 1997;43(2):120–124. doi: 10.1159/000291836. [DOI] [PubMed] [Google Scholar]
  20. FitzGerald M., Malone K. M., Li S., Harrison W. M., McBride P. A., Endicott J., Cooper T., Mann J. J. Blunted serotonin response to fenfluramine challenge in premenstrual dysphoric disorder. Am J Psychiatry. 1997 Apr;154(4):556–558. doi: 10.1176/ajp.154.4.556. [DOI] [PubMed] [Google Scholar]
  21. Freeman E. W., DeRubeis R. J., Rickels K. Reliability and validity of a daily diary for premenstrual syndrome. Psychiatry Res. 1996 Nov 15;65(2):97–106. doi: 10.1016/s0165-1781(96)02929-0. [DOI] [PubMed] [Google Scholar]
  22. Freeman E. W., Rickels K., Arredondo F., Kao L. C., Pollack S. E., Sondheimer S. J. Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. J Clin Psychopharmacol. 1999 Feb;19(1):3–8. doi: 10.1097/00004714-199902000-00002. [DOI] [PubMed] [Google Scholar]
  23. Freeman E. W., Rickels K., Sondheimer S. J., Polansky M. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry. 1999 Oct;56(10):932–939. doi: 10.1001/archpsyc.56.10.932. [DOI] [PubMed] [Google Scholar]
  24. Gehlert S., Hartlage S. A design for studying the DSM-IV research criteria of premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol. 1997 Mar;18(1):36–44. doi: 10.3109/01674829709085567. [DOI] [PubMed] [Google Scholar]
  25. Gilmore D. H., Hawthorn R. J., Hart D. M. Danol for premenstrual syndrome: a preliminary report of a placebo-controlled double-blind study. J Int Med Res. 1985;13(2):129–130. doi: 10.1177/030006058501300210. [DOI] [PubMed] [Google Scholar]
  26. Goldstein B. J., Goodnick P. J. Selective serotonin reuptake inhibitors in the treatment of affective disorders--III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol. 1998;12(3 Suppl B):S55–S87. doi: 10.1177/0269881198012003041. [DOI] [PubMed] [Google Scholar]
  27. Graham C. A., Sherwin B. B. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res. 1992 Apr;36(3):257–266. doi: 10.1016/0022-3999(92)90090-o. [DOI] [PubMed] [Google Scholar]
  28. Hahn P. M., Van Vugt D. A., Reid R. L. A randomized, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology. 1995;20(2):193–209. doi: 10.1016/0306-4530(94)00053-d. [DOI] [PubMed] [Google Scholar]
  29. Halbreich U., Smoller J. W. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry. 1997 Sep;58(9):399–402. doi: 10.4088/jcp.v58n0905. [DOI] [PubMed] [Google Scholar]
  30. Hammarbäck S., Bäckström T. Induced anovulation as treatment of premenstrual tension syndrome. A double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet Gynecol Scand. 1988;67(2):159–166. doi: 10.3109/00016348809004191. [DOI] [PubMed] [Google Scholar]
  31. Harrison W. M., Endicott J., Nee J. Treatment of premenstrual dysphoria with alprazolam. A controlled study. Arch Gen Psychiatry. 1990 Mar;47(3):270–275. doi: 10.1001/archpsyc.1990.01810150070011. [DOI] [PubMed] [Google Scholar]
  32. Helvacioglu A., Yeoman R. R., Hazelton J. M., Aksel S. Premenstrual syndrome and related hormonal changes. Long-acting gonadotropin releasing hormone agonist treatment. J Reprod Med. 1993 Nov;38(11):864–870. [PubMed] [Google Scholar]
  33. Hussain S. Y., Massil J. H., Matta W. H., Shaw R. W., O'Brien P. M. Buserelin in premenstrual syndrome. Gynecol Endocrinol. 1992 Mar;6(1):57–64. doi: 10.3109/09513599209081007. [DOI] [PubMed] [Google Scholar]
  34. Jermain D. M., Preece C. K., Sykes R. L., Kuehl T. J., Sulak P. J. Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study. Arch Fam Med. 1999 Jul-Aug;8(4):328–332. doi: 10.1001/archfami.8.4.328. [DOI] [PubMed] [Google Scholar]
  35. Johnson S. R., McChesney C., Bean J. A. Epidemiology of premenstrual symptoms in a nonclinical sample. I. Prevalence, natural history and help-seeking behavior. J Reprod Med. 1988 Apr;33(4):340–346. [PubMed] [Google Scholar]
  36. Johnson S. R. The epidemiology and social impact of premenstrual symptoms. Clin Obstet Gynecol. 1987 Jun;30(2):367–376. doi: 10.1097/00003081-198706000-00017. [DOI] [PubMed] [Google Scholar]
  37. Johnson W. G., Carr-Nangle R. E., Bergeron K. C. Macronutrient intake, eating habits, and exercise as moderators of menstrual distress in healthy women. Psychosom Med. 1995 Jul-Aug;57(4):324–330. doi: 10.1097/00006842-199507000-00003. [DOI] [PubMed] [Google Scholar]
  38. Kendler K. S., Karkowski L. M., Corey L. A., Neale M. C. Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiatry. 1998 Sep;155(9):1234–1240. doi: 10.1176/ajp.155.9.1234. [DOI] [PubMed] [Google Scholar]
  39. Kulin N. A., Pastuszak A., Sage S. R., Schick-Boschetto B., Spivey G., Feldkamp M., Ormond K., Matsui D., Stein-Schechman A. K., Cook L. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA. 1998 Feb 25;279(8):609–610. doi: 10.1001/jama.279.8.609. [DOI] [PubMed] [Google Scholar]
  40. Ladisich W. Influence of progesterone on serotonin metabolism: a possible causal factor for mood changes. Psychoneuroendocrinology. 1977;2(3):257–266. doi: 10.1016/0306-4530(77)90042-7. [DOI] [PubMed] [Google Scholar]
  41. London R. S., Bradley L., Chiamori N. Y. Effect of a nutritional supplement on premenstrual symptomatology in women with premenstrual syndrome: a double-blind longitudinal study. J Am Coll Nutr. 1991 Oct;10(5):494–499. doi: 10.1080/07315724.1991.10718176. [DOI] [PubMed] [Google Scholar]
  42. London R. S., Murphy L., Kitlowski K. E., Reynolds M. A. Efficacy of alpha-tocopherol in the treatment of the premenstrual syndrome. J Reprod Med. 1987 Jun;32(6):400–404. [PubMed] [Google Scholar]
  43. Meltzer H. Serotonergic dysfunction in depression. Br J Psychiatry Suppl. 1989 Dec;(8):25–31. [PubMed] [Google Scholar]
  44. Menkes D. B., Taghavi E., Mason P. A., Spears G. F., Howard R. C. Fluoxetine treatment of severe premenstrual syndrome. BMJ. 1992 Aug 8;305(6849):346–347. doi: 10.1136/bmj.305.6849.346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Merikangas K. R., Foeldenyi M., Angst J. The Zurich Study. XIX. Patterns of menstrual disturbances in the community: results of the Zurich Cohort Study. Eur Arch Psychiatry Clin Neurosci. 1993;243(1):23–32. doi: 10.1007/BF02191520. [DOI] [PubMed] [Google Scholar]
  46. Mira M., McNeil D., Fraser I. S., Vizzard J., Abraham S. Mefenamic acid in the treatment of premenstrual syndrome. Obstet Gynecol. 1986 Sep;68(3):395–398. doi: 10.1097/00006250-198609000-00022. [DOI] [PubMed] [Google Scholar]
  47. Mortola J. F., Girton L., Beck L., Yen S. S. Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: the calendar of premenstrual experiences. Obstet Gynecol. 1990 Aug;76(2):302–307. [PubMed] [Google Scholar]
  48. Mortola J. F., Girton L., Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab. 1991 Feb;72(2):252A–252F. doi: 10.1210/jcem-72-2-252. [DOI] [PubMed] [Google Scholar]
  49. Must A., Spadano J., Coakley E. H., Field A. E., Colditz G., Dietz W. H. The disease burden associated with overweight and obesity. JAMA. 1999 Oct 27;282(16):1523–1529. doi: 10.1001/jama.282.16.1523. [DOI] [PubMed] [Google Scholar]
  50. Nulman I., Rovet J., Stewart D. E., Wolpin J., Gardner H. A., Theis J. G., Kulin N., Koren G. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med. 1997 Jan 23;336(4):258–262. doi: 10.1056/NEJM199701233360404. [DOI] [PubMed] [Google Scholar]
  51. O'Brien P. M., Abukhalil I. E. Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase-only danazol. Am J Obstet Gynecol. 1999 Jan;180(1 Pt 1):18–23. doi: 10.1016/s0002-9378(99)70142-0. [DOI] [PubMed] [Google Scholar]
  52. O'Brien P. M., Craven D., Selby C., Symonds E. M. Treatment of premenstrual syndrome by spironolactone. Br J Obstet Gynaecol. 1979 Feb;86(2):142–147. doi: 10.1111/j.1471-0528.1979.tb10582.x. [DOI] [PubMed] [Google Scholar]
  53. Oleson T., Flocco W. Randomized controlled study of premenstrual symptoms treated with ear, hand, and foot reflexology. Obstet Gynecol. 1993 Dec;82(6):906–911. [PubMed] [Google Scholar]
  54. Ozeren S., Corakçi A., Yücesoy I., Mercan R., Erhan G. Fluoxetine in the treatment of premenstrual syndrome. Eur J Obstet Gynecol Reprod Biol. 1997 Jun;73(2):167–170. doi: 10.1016/s0301-2115(97)02741-3. [DOI] [PubMed] [Google Scholar]
  55. Pastuszak A., Schick-Boschetto B., Zuber C., Feldkamp M., Pinelli M., Sihn S., Donnenfeld A., McCormack M., Leen-Mitchell M., Woodland C. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac) JAMA. 1993 May 5;269(17):2246–2248. [PubMed] [Google Scholar]
  56. Pearlstein T. B., Frank E., Rivera-Tovar A., Thoft J. S., Jacobs E., Mieczkowski T. A. Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder. J Affect Disord. 1990 Oct;20(2):129–134. doi: 10.1016/0165-0327(90)90126-s. [DOI] [PubMed] [Google Scholar]
  57. Pearlstein T. B., Stone A. B., Lund S. A., Scheft H., Zlotnick C., Brown W. A. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol. 1997 Aug;17(4):261–266. doi: 10.1097/00004714-199708000-00004. [DOI] [PubMed] [Google Scholar]
  58. Prior J. C., Vigna Y., Sciarretta D., Alojado N., Schulzer M. Conditioning exercise decreases premenstrual symptoms: a prospective, controlled 6-month trial. Fertil Steril. 1987 Mar;47(3):402–408. doi: 10.1016/s0015-0282(16)59045-1. [DOI] [PubMed] [Google Scholar]
  59. Ramcharan S., Love E. J., Fick G. H., Goldfien A. The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: attributable risk and risk factors. J Clin Epidemiol. 1992 Apr;45(4):377–392. doi: 10.1016/0895-4356(92)90039-p. [DOI] [PubMed] [Google Scholar]
  60. Rapkin A. J. The role of serotonin in premenstrual syndrome. Clin Obstet Gynecol. 1992 Sep;35(3):629–636. doi: 10.1097/00003081-199209000-00022. [DOI] [PubMed] [Google Scholar]
  61. Rickels K., Freeman E., Sondheimer S. Buspirone in treatment of premenstrual syndrome. Lancet. 1989 Apr 8;1(8641):777–777. doi: 10.1016/s0140-6736(89)92591-9. [DOI] [PubMed] [Google Scholar]
  62. Rivera-Tovar A. D., Frank E. Late luteal phase dysphoric disorder in young women. Am J Psychiatry. 1990 Dec;147(12):1634–1636. doi: 10.1176/ajp.147.12.1634. [DOI] [PubMed] [Google Scholar]
  63. Rojansky N., Halbreich U., Zander K., Barkai A., Goldstein S. Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes. Gynecol Obstet Invest. 1991;31(3):146–152. doi: 10.1159/000293135. [DOI] [PubMed] [Google Scholar]
  64. Rosen R. C., Lane R. M., Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999 Feb;19(1):67–85. doi: 10.1097/00004714-199902000-00013. [DOI] [PubMed] [Google Scholar]
  65. Rubinow D. R., Schmidt P. J. The treatment of premenstrual syndrome--forward into the past. N Engl J Med. 1995 Jun 8;332(23):1574–1575. doi: 10.1056/NEJM199506083322309. [DOI] [PubMed] [Google Scholar]
  66. Sances G., Martignoni E., Fioroni L., Blandini F., Facchinetti F., Nappi G. Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache. 1990 Nov;30(11):705–709. doi: 10.1111/j.1526-4610.1990.hed3011705.x. [DOI] [PubMed] [Google Scholar]
  67. Sayegh R., Schiff I., Wurtman J., Spiers P., McDermott J., Wurtman R. The effect of a carbohydrate-rich beverage on mood, appetite, and cognitive function in women with premenstrual syndrome. Obstet Gynecol. 1995 Oct;86(4 Pt 1):520–528. doi: 10.1016/0029-7844(95)00246-n. [DOI] [PubMed] [Google Scholar]
  68. Schmidt P. J., Nieman L. K., Danaceau M. A., Adams L. F., Rubinow D. R. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998 Jan 22;338(4):209–216. doi: 10.1056/NEJM199801223380401. [DOI] [PubMed] [Google Scholar]
  69. Smith S., Rinehart J. S., Ruddock V. E., Schiff I. Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet Gynecol. 1987 Jul;70(1):37–43. [PubMed] [Google Scholar]
  70. Steinberg S., Annable L., Young S. N., Liyanage N. A placebo-controlled clinical trial of L-tryptophan in premenstrual dysphoria. Biol Psychiatry. 1999 Feb 1;45(3):313–320. doi: 10.1016/s0006-3223(98)00005-5. [DOI] [PubMed] [Google Scholar]
  71. Steiner M., Korzekwa M., Lamont J., Wilkins A. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol Bull. 1997;33(4):771–774. [PubMed] [Google Scholar]
  72. Steiner M., Lamont J., Steinberg S., Stewart D., Reid R., Streiner D. Effect of fluoxetine on menstrual cycle length in women with premenstrual dysphoria. Obstet Gynecol. 1997 Oct;90(4 Pt 1):590–595. doi: 10.1016/s0029-7844(97)00307-4. [DOI] [PubMed] [Google Scholar]
  73. Steiner M., Steinberg S., Stewart D., Carter D., Berger C., Reid R., Grover D., Streiner D. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med. 1995 Jun 8;332(23):1529–1534. doi: 10.1056/NEJM199506083322301. [DOI] [PubMed] [Google Scholar]
  74. Steiner M., Streiner D. L., Steinberg S., Stewart D., Carter D., Berger C., Reid R., Grover D. The measurement of premenstrual mood symptoms. J Affect Disord. 1999 Jun;53(3):269–273. doi: 10.1016/s0165-0327(98)00121-9. [DOI] [PubMed] [Google Scholar]
  75. Steiner M, Yatham LN, Coote M, Wilkins A, Lepage P. Serotonergic dysfunction in women with pure premenstrual dysphoric disorder: is the fenfluramine challenge test still relevant? Psychiatry Res. 1999 Oct 11;87(2-3):107–115. doi: 10.1016/s0165-1781(99)00062-1. [DOI] [PubMed] [Google Scholar]
  76. Stone A. B., Pearlstein T. B., Brown W. A. Fluoxetine in the treatment of late luteal phase dysphoric disorder. J Clin Psychiatry. 1991 Jul;52(7):290–293. [PubMed] [Google Scholar]
  77. Su T. P., Schmidt P. J., Danaceau M. A., Tobin M. B., Rosenstein D. L., Murphy D. L., Rubinow D. R. Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmacology. 1997 May;16(5):346–356. doi: 10.1016/S0893-133X(96)00245-X. [DOI] [PubMed] [Google Scholar]
  78. Sundblad C., Hedberg M. A., Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology. 1993 Sep;9(2):133–145. doi: 10.1038/npp.1993.52. [DOI] [PubMed] [Google Scholar]
  79. Sundblad C., Modigh K., Andersch B., Eriksson E. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand. 1992 Jan;85(1):39–47. doi: 10.1111/j.1600-0447.1992.tb01440.x. [DOI] [PubMed] [Google Scholar]
  80. Thys-Jacobs S., Ceccarelli S., Bierman A., Weisman H., Cohen M. A., Alvir J. Calcium supplementation in premenstrual syndrome: a randomized crossover trial. J Gen Intern Med. 1989 May-Jun;4(3):183–189. doi: 10.1007/BF02599520. [DOI] [PubMed] [Google Scholar]
  81. Thys-Jacobs S., Starkey P., Bernstein D., Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol. 1998 Aug;179(2):444–452. doi: 10.1016/s0002-9378(98)70377-1. [DOI] [PubMed] [Google Scholar]
  82. Vellacott I. D., Shroff N. E., Pearce M. Y., Stratford M. E., Akbar F. A. A double-blind, placebo-controlled evaluation of spironolactone in the premenstrual syndrome. Curr Med Res Opin. 1987;10(7):450–456. doi: 10.1185/03007998709112403. [DOI] [PubMed] [Google Scholar]
  83. Walker A. F., De Souza M. C., Vickers M. F., Abeyasekera S., Collins M. L., Trinca L. A. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J Womens Health. 1998 Nov;7(9):1157–1165. doi: 10.1089/jwh.1998.7.1157. [DOI] [PubMed] [Google Scholar]
  84. Wang M., Hammarbäck S., Lindhe B. A., Bäckström T. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand. 1995 Nov;74(10):803–808. doi: 10.3109/00016349509021201. [DOI] [PubMed] [Google Scholar]
  85. Wikander I., Sundblad C., Andersch B., Dagnell I., Zylberstein D., Bengtsson F., Eriksson E. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol. 1998 Oct;18(5):390–398. doi: 10.1097/00004714-199810000-00007. [DOI] [PubMed] [Google Scholar]
  86. Wood S. H., Mortola J. F., Chan Y. F., Moossazadeh F., Yen S. S. Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. Obstet Gynecol. 1992 Sep;80(3 Pt 1):339–344. [PubMed] [Google Scholar]
  87. Wurtman J. J. Depression and weight gain: the serotonin connection. J Affect Disord. 1993 Oct-Nov;29(2-3):183–192. doi: 10.1016/0165-0327(93)90032-f. [DOI] [PubMed] [Google Scholar]
  88. Wyatt K. M., Dimmock P. W., Jones P. W., Shaughn O'Brien P. M. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ. 1999 May 22;318(7195):1375–1381. doi: 10.1136/bmj.318.7195.1375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Yatham L. N. Is 5HT1A receptor subsensitivity a trait marker for late luteal phase dysphoric disorder? A pilot study. Can J Psychiatry. 1993 Dec;38(10):662–664. doi: 10.1177/070674379303801007. [DOI] [PubMed] [Google Scholar]
  90. Yonkers K. A., Halbreich U., Freeman E., Brown C., Endicott J., Frank E., Parry B., Pearlstein T., Severino S., Stout A. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA. 1997 Sep 24;278(12):983–988. [PubMed] [Google Scholar]
  91. Young S. A., Hurt P. H., Benedek D. M., Howard R. S. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry. 1998 Feb;59(2):76–80. doi: 10.4088/jcp.v59n0206. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Psychiatry and Neuroscience are provided here courtesy of Canadian Medical Association

RESOURCES